Oruka Therapeutics (ORKA) Accumulated Expenses (2010 - 2026)

Oruka Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $9.3 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 63.99% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $9.3 million, a 63.99% increase from a year earlier, with the FY2025 full-year figure at $5.3 million, up 158.01% from the prior year.
• Accumulated Expenses rose to $9.3 million in Q1 2026 per ORKA's latest filing, from $5.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $9.3 million in Q1 2026 and bottomed at $84000.0 in Q1 2024.
• The 5-year median for Accumulated Expenses is $324000.0 (2022), against an average of $2.2 million.
• Across the five-year window, Accumulated Expenses slumped 81.3% in 2022 and jumped 6641.67% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $173000.0 in 2022, then tumbled by 42.2% to $100000.0 in 2023, then jumped by 1941.0% to $2.0 million in 2024, then surged by 158.01% to $5.3 million in 2025, then soared by 76.36% to $9.3 million in 2026.
• Per Business Quant, the three latest ORKA Accumulated Expenses figures stand at $9.3 million (Q1 2026), $5.3 million (Q4 2025), and $8.6 million (Q3 2025).